Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 131-137

  Cotroneo, Antonino Maria ^a   Castagna, Alberto ^b   Putignano, Salvatore ^c   Lacava, Roberto ^b   Fantò, Fausto ^d   Monteleone, Francesco ^e   Rocca, Filomena ^b   Malara, Alba ^b   Gareri, Pietro ^b  

^a ASL 2 Turin   (United States)

^b ASP Catanzaro   (Italy)

^c ASL Napoli 1   (Italy)

^d University Hospital Orbassano   (Italy)

^e Regina Margherita Hospital   (Italy)

Author keywords

Citicoline; Effectiveness; Elderly; Safety; Vascular mild cognitive impairment

Indexed keywords

CITICOLINE; CYANOCOBALAMIN; DOPAMINE; FOLIC ACID; NORADRENALIN; PHOSPHOLIPID; THYROID HORMONE;

ACTIVITIES OF DAILY LIVING SCALE; AGED; ARTICLE; BEHAVIOR DISORDER; BRAIN HYPOXIA; BRAIN ISCHEMIA; BRAIN METABOLISM; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CUMULATIVE ILLNESS RATING SCALE; DEPENDENT PERSONALITY DISORDER; DIGESTIVE INTOLERANCE; DOPAMINE BRAIN LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; EXCITABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GERIATRIC DEPRESSION SCALE; HUMAN; INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; ITALY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MILD VASCULAR COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MOOD DISORDER; MULTICENTER STUDY; NEUROPROTECTION; NEUROPSYCHIATRIC INVENTORY SCALE; NORADRENALIN BRAIN LEVEL; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; PHOSPHOLIPID SYNTHESIS; RATING SCALE; RESTLESSNESS; SIDE EFFECT; THYROID HORMONE BLOOD LEVEL; VITAMIN BLOOD LEVEL;

CITICOLINE; EFFECTIVENESS; ELDERLY; SAFETY; VASCULAR MILD COGNITIVE IMPAIRMENT;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; CYTIDINE DIPHOSPHATE CHOLINE; DEPRESSION; FEMALE; FOLIC ACID; GERIATRIC ASSESSMENT; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL DISORDERS; MILD COGNITIVE IMPAIRMENT; NOOTROPIC AGENTS; THYROID HORMONES; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR DISEASES; VITAMIN B 12;

EID: 84873673270     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S38420     Document Type: Article

References (23)

1. Jokinen H, Lipsanen J, Schmidt R, etal; LADIS Study Group. Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. Neurology. 2012;78:1785-1792.
2. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1:426-436.
3. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002;70:133-139.
4. Alvarez XA, Laredo M, Corzo D, et al. Citicoline improves memory performances in elderly subjects. Methods Find Exp Clin Pharmacol. 1997;19:201-210.
5. Caamano J, Gomez MJ. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1994;16:211-218.
6. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J Neurol Sci. 2007;257:264-269.
7. Cacabelos R, Caamano J. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics and immune factors. Ann N Y Acad Sci. 1996;777:399-403.
8. Fioravanti M, Yanagi M. Cytidine diphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005; 2:CD000269.
9. Lozano-Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in 2817 cases. Arzneimittelforschung. 1983;33(7A):1073-1080.
10. Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008;5:167-177.
11. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol. 1995;17 Suppl B:1-54.
12. Clark WM. Efficacy of citicoline as an acute stroke treatment. Expert Opin Pharmacother. 2009;10:839-846.
13. Hurtado O, Lizasoain I, Moro MA. Neuroprotection and recovery: recent data at the bench on citicoline. Stroke. 2011;42 Suppl 1:S33-S35.
14. Lee HJ, Kang JS, Kim YI. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. J Clin Neurol. 2009;5:33-38.
15. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol. 2006;28 Suppl B:1-56.
16. Secades JJ. CDP-choline: update and review of its pharmacology and clinical use. Methods Find Exp Clin Pharmacol. 2002;24 Suppl B:1-53.
17. Secades JJ. CDP-choline and clinical review, 2010 update. Rev Neurol. 2011;52 Suppl 2:S1-S62.
18. Secades JJ. Probable role of citicoline in stroke rehabilitation: review of the literature. Rev Neurol. 2012;54:173-179.
19. Teather LA, Wurtman RJ. Dietary cytidine (5′)-diphosphocholine supplementation protects against development of memory deficits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:711-717.
20. Teather LA, Wurtman RJ. Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats. Learn Mem. 2005;12:39-43.
21. Alvarez-Sabin J, Roman GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011;42 Suppl 1:S40-S43.
22. Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernandez M, Diez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. Neurol Sci. 2010;299:188-192.
23. Putignano S, Gareri P, Castagna A, et al. Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome. Clin Interv Aging. 2012;7:113-118.